Human cytomegalovirus (HCMV) load and virus-specific IgM were quantified in blood of 36 fetuses from mothers with primary HCMV infection. Nineteen fetuses were congenitally infected and 17 were uninfected as diagnosed by virus isolation from and DNA detection in amniotic fluid. Sensitivity of antigenemia was 57.9%; of viremia, 55.5%; of leukoDNAemia, 82.3%; and of IgM, 57.9%; specificity was 100% for all assays. When amniocentesis was performed, 4 HCMV-infected fetuses (group A) showed abnormal ultrasound and biochemical/ hematologic findings, 8 (group B) had elevated g-glutamyl transferase values, and 7 (group C) had normal ultrasound and biochemical findings. Virus loads were higher in groups A and B than in group C. In group A, no pregnancy went to term, in group B, 3 of 6 newborns were symptomatic at birth, and in group C, the 6 newborns were subclinically infected. Taken together, virologic, laboratory, and ultrasound findings may contribute to a better prognostic definition of fetal HCMV infection.
Human cytomegalovirus (HCMV) is the etiologic agent of the most common congenital virus infection in humans (occurring in 0.2%-2.2% of all live births). Congenital HCMV infection is silent at birth in 90% of infants, yet 5%-17% of these neonates will develop neurological impairment [1] . Congenital HCMV infection can be diagnosed antenatally by virus isolation from or viral DNA detection in amniotic fluid [2, 3] ; however, the value of the IgM determination in fetal blood has never been fully assessed [2, [4] [5] [6] . While several studies established the diagnostic and prognostic value of HCMV antigenemia, viremia, and leukoDNAemia (L-DNAemia) in peripheral blood leukocytes (PBLs) of immunocompromised persons [7] , the presence of the virus or viral components in blood has never been fully investigated in fetuses exposed to HCMV. The present study was done retrospectively to assess the diagnostic and prognostic significance of different HCMV assays in fetal blood.
Materials and Methods
Subjects and samples. The following subjects were examined: 21 fetuses (including 1 set of twins) with HCMV infection (group 1), 15 fetuses without HCMV infection (group 2), and 11 newborns with congenital HCMV infection who had been examined as fetuses in group 1 (group 3). Prenatal diagnosis was done at 18-27 weeks of gestation (median, 21) by amniocentesis and fetal blood sampling under ultrasound guidance. We indirectly confirmed the purity of fetal blood in each instance by observing the tip of the needle within the fetal vessel (the umbilical vein at the placental cord insertion or at its intrahepatic tract). In addition, all fetal blood samples had red blood cell counts done, and the values were confirmed to be within the reference range for gestational age, which ruled out significant hemodilution. Amniotic fluid samples were discarded if grossly contaminated with blood. Diagnosis of congenital HCMV infection was made from amniotic fluid samples; PBLs were used to determine the virologic parameters under investigation and plasma samples to determine virus-specific IgM. We retrospectively examined blood samples from each of the three groups (30, 15, and 11 blood samples, respectively) for antigenemia, viremia, L-DNAemia, and virus-specific IgM. The fetuses were from 35 mothers who developed primary HCMV infection during pregnancy, which had been diagnosed by seroconversion ( ); n = 11 by clinical symptoms (fever, myalgia), abnormal liver enzyme values, and/or presence of virus-specific IgM ( ); or by presence n = 18 of IgM and pp65 antigenemia or L-DNAemia ( ) [8] . n = 6 Diagnosis of congenital HCMV infection. Congenital HCMV infection was diagnosed antenatally by virus isolation from and viral DNA detection in amniotic fluid as previously described [2, 3] and at birth by virus recovery from urine.
Serology. HCMV-specific IgG and IgM were determined by ELISAs developed in the laboratory [9, 10] . A ratio (R) value of 1 indicated presence of virus-specific IgM.
pp65 antigenemia and viremia quantitation. cells examined on cytospin preparations stained as de- 5 2 ϫ 10 scribed elsewhere [11] . Viremia was quantitated by counting the number of fibroblast nuclei positive for HCMV-immediate early antigen p72 16-24 h after inoculation of PBLs onto human 5 2 ϫ 10 embryonic lung fibroblast (HELF, originally developed in our laboratory) cell cultures in shell vials [12] . Both assays were performed prospectively.
L-DNAemia quantitation. L-DNAemia relevant to exon 4 of the major immediate early gene was quantitated in 10 5 PBLs (0.5 mg of DNA) by polymerase chain reaction (PCR) [13] with some modifications [2, 8] . In brief, an internal control of amplification was routinely coamplified to detect PCR inhibitors. Samples negative for HCMV DNA but competent for amplification, as shown by PCR product of the internal control, were submitted to a second (nested) step of amplification. By means of single-step PCR, samples containing 110 genome equivalents (GE) were consistently amplified, whereas in the nested assay samples containing 1-10 GE could be detected, which were assigned an arbitrary value of 5 GE. L-DNAemia was determined retrospectively on PBL aliquots stored at Ϫ80ЊC.
Virus isolation. Early virus identification was achieved 16-24 h after inoculation of clinical samples (amniotic fluid, urine) onto HELF monolayers grown in shell vials [12] . Conventional virus isolation from PBLs or other clinical samples was performed as reported [12] .
Statistics.
Data were compared between groups with the Mann-Whitney rank-sum test; differences in percentages were compared by the x 2 test.
Results

Diagnosis of congenital HCMV infection.
Of the 36 fetuses studied, 16 were infected with HCMV, and 20 were uninfected. Congenital HCMV infection was confirmed at birth or after termination of pregnancy in all 16 cases of positive prenatal diagnosis; 5 (25%) of the 20 fetuses with negative prenatal diagnoses were found at birth to be HCMV infected. Retrospective testing of amniotic fluid samples by an improved nested PCR protocol [3] allowed detection of very low amounts of viral DNA in 3 of 4 discrepant amniotic fluid samples that were available for retesting (table 1, fetuses 14, 15, and 17). Thus, at the time of amniocentesis, HCMV infection was considered to be absent in 15 (41.6%) fetuses, present in 19 (52.8%), and possibly present in the remaining 2 (5.5%; 1 was negative by the improved nested PCR assay, and 1 was not available for retesting).
Clinical grouping of congenital infection. Fetuses were divided into 3 groups (table 1, groups A-C) on the basis of ul- 
Analysis of virologic parameters.
In the group of congenitally infected fetuses, L-DNAemia appeared to be the most sensitive assay (82.3% sensitivity), followed by antigenemia and IgM determination (57.9% for both), and by viremia (55.5%).
Overall mean values were as follows: for antigenemia, 16. Higher levels of all virologic parameters were detected in the groups of fetuses with abnormalities (groups A and B) than in fetuses with normal findings (group C), although only antigenemia and IgM reached levels of significance ( and .02, P = .05 respectively). Mean values and ranges of different virologic parameters for the 3 groups of fetuses are shown in table 2. Four of 4 fetuses in group A and 5 (62.5%) of 8 in group B were IgM positive compared with only 2 (28.5%) of 7 normal fetuses. When the distribution of IgM antibody response in groups A and B was compared to that in group C, the difference was significant ( ) and did not appear to be related to the P = .05 time of maternal infection, to the interval between onset of maternal infection and prenatal diagnosis, or to the week of pregnancy at amniocentesis (table 1) .
Term pregnancies. As shown in table 1, 11 (61.1%) of 18 pregnancies (including the twin gestation) went to term, and virologic data were available for 11 (91.7%) of the 12 newborns. Antigenemia was positive in 6 of 12 fetuses (nos. 7, 8, [10] [11] [12] 19 ) and in 6 newborns, 3 of whom (nos. 9, 16, 17) were negative antenatally. Viremia was positive in 4 fetuses (nos. 10-12, 19), 2 of whom (nos. 11 and 12) had comparable high levels (69 and 70 p72-positive fibroblasts, respectively). Yet only 1 newborn (no. 12), who showed severe congenital HCMV disease, was still viremic at birth; an additional newborn (no. 16) who was negative in utero was also positive at birth. In addition, all 6 L-DNAemia-positive fetuses (nos. 7, 8, [10] [11] [12] 19) were still positive at birth. On the other hand, both twins who were L-DNAemia negative antenatally (nos. 14, 15), had detectable viral DNA (5 GE) at birth. Finally, IgM was present in 4 (33.3%) of 12 fetuses (nos. 7, 8, 12, 16 ) and in 7 (63.6%) of 11 newborns, 3 of whom (nos. 13-15) were negative prenatally.
Discussion
In this study, HCMV load in PBLs was quantified in fetuses with congenital HCMV infection by measuring pp65 antigenemia, viremia, L-DNAemia, and virus-specific IgM to establish the diagnostic value and prognostic significance of these virologic parameters. Results indicate that no assay is sensitive enough to significantly improve prenatal diagnosis of intrauterine transmission of the infection, compared with diagnosis by virus isolation from or viral DNA detection in amniotic fluid. Viremia was negative in the only 8 HCMV-infected fetuses previously examined by others [14] . In our study, HCMV load was quantified for the first time in fetal blood. Although only antigenemia and IgM reached levels of significance, we observed that the levels of all virologic parameters as well as IgM antibody were higher in the fetuses with ultrasound or clinical/ laboratory abnormalities than in normal fetuses.
The observation that the frequency of IgM positivity is significantly higher in groups A and B than in group C is intriguing. This finding might be explained by the fact that IgMnegative fetuses were sampled in the early phase of HCMV infection. This hypothesis seems to be supported by the finding that 4 of the 7 IgM-negative fetuses had virus-specific IgM at birth and that an additional newborn developed a specific IgM response 65 days after birth. Possible additional evidence that they were sampled early during the infection (or, alternatively, that they experienced a mild HCMV infection) is the observation that the great majority of these fetuses had normal biochemical and hematologic values and low virus load in blood.
Finally, 3 fetuses with normal laboratory tests, who were diagnosed as congenitally infected only by retrospective testing of amniotic fluid by a very sensitive nested PCR assay [3] , were L-DNAemia positive at birth. This, too, supports the hypothesis that blood was taken at an early phase of the HCMV fetal infection. Taken together, these data seem to justify the conclusion that fetuses with normal biochemical/hematologic and ultrasound findings, low or no HCMV load in PBLs, and undetectable virus-specific IgM antibody at 20-24 weeks of gestation may have a more favorable outcome.
It has been previously suggested that grossly abnormal laboratory or ultrasonographic findings are more likely associated with important sequelae or severe disease at birth. In our study, none of the pregnancies with abnormal ultrasound and biochemical/hematologic findings went to term. However, 3 of 6 delivered fetuses with altered gGT values were symptomatic at birth. Of interest, these 3 symptomatic newborns had detectable virus-specific IgM antenatally, whereas the 3 delivered newborns with subclinical HCMV infection were IgM negative when tested in utero. This finding, within the limits of the restricted number of fetuses examined, may further support the potential utility of this parameter as a prognostic marker.
In conclusion, since a virologic follow-up is unfeasible in utero, we believe it remains very difficult to predict the outcome of HCMV infection using results of a single blood sample. However, the simultaneous determination of multiple virologic parameters concomitantly with laboratory and ultrasound findings may yield a better prognostic definition of the fetal infection.
